Solenn Brosseau

Solenn Brosseau

Auto-generated profile, based on publicly available information

Solenn Brosseau

Université Paris-Cité, Department of Thoracic Oncology, CIC INSERM 1425, Hôpital Bichat, APHP.Nord, Paris, France

Research Focus & Metrics

Academic Career Length

10Years (2017-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
12 April 2019 in Journal of Experimental & Clinical Cancer Research
Verified
Journal Article
Open access
PDF file
MKMaureen Keller
Maureen Keller
FDFatéméh Dubois
Fatéméh Dubois
STSylvain Teulier
Sylvain Teulier
AMAlexandre P. J. Martin
Alexandre P. J. Martin
JLJérôme Levallet
Jérôme Levallet
GLGuénaëlle Levallet
Guénaëlle Levallet
RASSF1A, a tumor suppressor gene, is frequently inactivated in lung cancer leading to a YAP-dependent epithelial-mesenchymal transition (EMT). Such effects are partly due to the inactivation of the anti-migratory RhoB GTPase via the inhibitory phosphorylation of GEF-H1, the GDP/GTP exchange factor for RhoB. However, the kinase responsible for RhoB/GEF-H1 inactivation in RASSF1A-depleted cells remained unknown. NDR1/2 inactivation by siRNA or shRNA effects on epithelial-mesenchymal transition, invasion, xenograft formation and growth in SCID−/− Beige mice, apoptosis, proliferation, cytokinesis, YAP/TAZ activation were investigated upon RASSF1A loss in human bronchial epithelial cells (HBEC). We demonstrate here that depletion of the YAP-kinases NDR1/2 reverts migration and metastatic properties upon RASSF1A loss in HBEC. We show that NDR2 interacts directly with GEF-H1 (which contains the NDR phosphorylation consensus motif HXRXXS/T), leading to GEF-H1 phosphorylation. We further report that the RASSF1A/NDR2/GEF-H1/RhoB/YAP axis is involved in proper cytokinesis in human bronchial cells, since chromosome proper segregation are NDR-dependent upon RASSF1A or GEF-H1 loss in HBEC. To summarize, our data support a model in which, upon RASSF1A silencing, NDR2 gets activated, phosphorylates and inactivates GEF-H1, leading to RhoB inactivation. This cascade induced by RASSF1A loss in bronchial cells is responsible for metastasis properties, YAP activation and cytokinesis defects.

11 August 2022 in Cancers
Verified
Journal Article
Open access
PDF file
NGNadia Guezour
Nadia Guezour
Ghassen SoussiGhassen Soussi
Ghassen Soussi
SBSolenn Brosseau
Solenn Brosseau
BABaptiste Abbar
Baptiste Abbar
CNCharles Naltet
Charles Naltet
VGValérie Gounant
Valérie Gounant
Background: Immune checkpoint inhibitors (ICIs) have been a major advance in treating non-small-cell lung cancer (NSCLC). Programmed cell death protein-1/programmed death-ligand 1 blockade enhances immune function, mediating anti-tumor activity, yet causing immune-related adverse events (irAEs). We investigated the prognostic role of Grade 3–4 irAEs on overall survival (OS). Methods: This observational study recruited advanced NSCLC patients who received ICIs at Bichat-Claude Bernard University Hospital and in a community hospital, Saint-Joseph Foundation (Paris), between 1 January 2016 and 31 December 2019. Immunotherapy as a single-agent or double-drug combination was applied in the first and later lines. Univariable and multivariable analyses were instrumental in evaluating the prognostic impact of irAEs. Results: Overall, 201 consecutive ICI-treated patients were enrolled. High-grade irAEs (Grades 3–4) occurred in 36 patients (17.9%), including 11 (30.5%) cases of pneumonitis, 8 (22.2%) of colitis, 4 (11.1%) hepatic, 3 (8.3%) dermatological, 2 (5.5%) neurological events, and 2 cases (5.5%) of poly-arthralgia. The median OS was 10.4 ± 1.36 months (95% CI:7.7–13.1), being significantly higher in patients with high-grade irAEs than those without, 27.8 months vs. 8.1 months, respectively (HR = 2.5; p < 0.0001). Multivariable analysis revealed an independent association between high-grade irAEs and longer OS (HR = 0.29, 95% CI: 0.2–0.6, p < 0.0001). Conclusions: Our real-life study confirms that high-grade irAEs predict longer OS in advanced NSCLC.

1 August 2021 in Lung Cancer
Verified
Journal Article
Closed access
ALArmelle Lavole
Armelle Lavole
JMJulien Mazieres
Julien Mazieres
SSSophie Schneider
Sophie Schneider
SBSolenn Brosseau
Solenn Brosseau
LKLize Kiakouama
Lize Kiakouama
JCJacques Cadranel
Jacques Cadranel

18 September 2017 in Annals of Oncology
Verified
Journal Article
Open access
PDF file
Roberto FerraraRoberto Ferrara
Roberto Ferrara
CCC. Caramella
C. Caramella
MTM. Texier
M. Texier
CVC. Audigier Valette
C. Audigier Valette
LTL. Tessonnier
L. Tessonnier
BBBenjamin Besse
Benjamin Besse
Background: Using Tumor Growth Rate (TGR), we previously described HPD in 10% of 89 NSCLC pts treated with IO in a single institution. In this retrospective study, we explored HPD in a larger and multicenter cohort of advanced NSCLC pts treated with IO.

17 March 2022 in Cells
Verified
Journal Article
Open access
PDF file
MBMarine Baron
Marine Baron
CSCathia Soulié
Cathia Soulié
ALArmelle Lavolé
Armelle Lavolé
LALambert Assoumou
Lambert Assoumou
BABaptiste Abbar
Baptiste Abbar
TGThe ANRS Co 24 OncoVIHAC Study Group
The ANRS Co 24 OncoVIHAC Study Group
The role of immune checkpoints (ICPs) in both anti-HIV T cell exhaustion and HIV reservoir persistence, has suggested that an HIV cure therapeutic strategy could involve ICP blockade. We studied the impact of anti-PD-1 therapy on HIV reservoirs and anti-viral immune responses in people living with HIV and treated for cancer. At several timepoints, we monitored CD4 cell counts, plasma HIV-RNA, cell associated (CA) HIV-DNA, EBV, CMV, HBV, HCV, and HHV-8 viral loads, activation markers, ICP expression and virus-specific T cells. Thirty-two patients were included, with median follow-up of 5 months. The CA HIV-DNA tended to decrease before cycle 2 (p = 0.049). Six patients exhibited a ≥0.5 log10 HIV-DNA decrease at least once. Among those, HIV-DNA became undetectable for 10 months in one patient. Overall, no significant increase in HIV-specific immunity was observed. In contrast, we detected an early increase in CTLA-4 + CD4+ T cells in all patients (p = 0.004) and a greater increase in CTLA-4+ and TIM-3 + CD8+ T cells in patients without HIV-DNA reduction compared to the others (p ≤ 0.03). Our results suggest that ICP replacement compensatory mechanisms might limit the impact of anti-PD-1 monotherapy on HIV reservoirs, and pave the way for combination ICP blockade in HIV cure strategies.

27 July 2017 in European Respiratory Journal
Verified
Journal Article
Open access
PDF file
JPJohan PLUVY
Johan PLUVY
SBSolenn Brosseau
Solenn Brosseau
CNCharles Naltet
Charles Naltet
MOMarie-Agnès Opsomer
Marie-Agnès Opsomer
ACAurélie Cazes
Aurélie Cazes
VGValérie Gounant
Valérie Gounant
Nivolumab appears efficacious in highly PD-L1-expressing NSCLC with poor PS, resulting in Lazarus syndromehttp://ow.ly/X92e30coTsB